NDAORALTABLET
Approved
Sep 2007
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
11
Data completeness
6/8 — Strong
AZOR (amlodipine besylate and olmesartan medoxomil) by Cosette is . Approved for hypertension, alone, other antihypertensive agents and 2 more indications. First approved in 2007.
Drug data last refreshed 21h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AZOR is a fixed-dose combination oral tablet containing amlodipine besylate (a calcium channel blocker) and olmesartan medoxomil (an angiotensin II receptor blocker) indicated for hypertension and heart failure management. The dual mechanism reduces blood pressure through peripheral vasodilation and renin-angiotensin system blockade. It is used as monotherapy or in combination with other antihypertensive agents.
$0.003BPart D
LOE ApproachingDeclining
Declining spending and approaching loss of exclusivity signals team consolidation and transition focus toward managed care and generics coordination.
Mechanism of Action
. Azor is a combination of two antihypertensive drugs: a dihydropyridine calcium antagonist (calcium ion antagonist or slow-channel blocker), amlodipine besylate, and an angiotensin II receptor blocker, olmesartan medoxomil. The amlodipine component of Azor inhibits the transmembrane influx of…
Worked on AZOR at Cosette? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.